New York, NY -- April 19, 2022 -- InvestorsHub NewsWire -- via Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies issues new research reports and a hot new featured stock report.

The company advancing the PHILUX Global Funds, PHI Group, Inc. (OTCPNK: PHIL) announced earlier this month that an agreement has been reached between Vietnam-based Ngoc Thien Phu Rice Export Import JSC (NTP) and PHI Group, Inc. to participate in PHILUX Global Food Fund (“PGFF”). According to the agreement, NTP will contribute a mutually agreed amount of capital for the setup and initial operating budget of the PGFF and hold 49% ownership of the general partners’ portion of this fund. PGFF will focus on food and food-related agricultural investment opportunities in Vietnam and other countries as well. Healthy living property developer, Alset EHome International Inc. (NASDAQ: AEI) released its FYE 2021 financials and it seems the company is doing well. The Group's revenue rose 21.9% to approximately $19.8 million in FY2021 from $16.2 million in FY2020 due primarily to an increase in revenue from its biohealth business and rental income under its real estate business. The Group's cash has more than doubled from approximately $25.0 million as of December 31, 2020, to $56.1 million as of December 31, 2021.

Find out more about NTP and the PHIL agreement and find out who has been buying up shares of AEI and more in the full report READ MORE
Copy and paste to browser may be required -

The late-stage biotechnology company CytoDyn Inc. (OTCQB: CYDY) is developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, has announced the publication of a peer-reviewed research paper entitled “Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species” in the open-access journal PLOS Pathogens. The study followed five HIV+ human participants who, after successfully transitioning to once weekly subcutaneous leronlimab, halted their previous daily oral antiretroviral therapy regimens. Argentum 47, Inc. (OTCPNK: ARGQ) has announced that management has fully executed a legally binding letter of intent to acquire UK based company, The Data Source Limited (TDS). Management has been in negotiations with several parties since late 2021 in order to successfully complete a merger or acquisition. TDS is a data driven B2B and B2C solutions provider utilizing artificial intelligence with lead generation, automation, and analytics. TDS provides its clients with world class data with the aim of becoming a one-stop-shop for all things data.

Get the details from the CYDY research paper and find out what the acquisition by ARGQ could mean to shareholders READ MORE
Copy and paste to browser may be required -


Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at:

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Traders News Source


Argentum 47 (PK) (USOTC:ARGQ)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Argentum 47 (PK) Charts.
Argentum 47 (PK) (USOTC:ARGQ)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Argentum 47 (PK) Charts.